Purple Biotech Reports Final CM24 Pancreatic Cancer Data
Ticker: PPBT · Form: 6-K · Filed: Apr 30, 2025 · CIK: 1614744
Sentiment: bullish
Topics: clinical-trial-data, oncology, pancreatic-cancer
TL;DR
Purple Biotech's CM24 shows promise in pancreatic cancer Phase 2 study.
AI Summary
Purple Biotech Ltd. announced final data from its Phase 2 study of CM24 in pancreatic cancer patients at the AACR 2025 Annual Meeting on April 30, 2025. The study showed improved outcomes and significant efficacy.
Why It Matters
Positive final data from a Phase 2 study could advance the development of CM24 as a treatment for pancreatic cancer, a notoriously difficult-to-treat disease.
Risk Assessment
Risk Level: medium — Clinical trial results, especially in oncology, carry inherent risks and are subject to further validation in larger trials.
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer of the report and company developing CM24
- CM24 (drug) — Investigational drug studied in pancreatic cancer
- AACR 2025 Annual Meeting (event) — Where the final data was presented
FAQ
What specific outcomes were improved in the Phase 2 study of CM24?
The filing states 'improved outcomes and significant efficacy' but does not provide specific metrics in this summary.
When was the final data from the Phase 2 study announced?
The final data was announced on April 30, 2025.
What type of cancer is CM24 being studied for?
CM24 is being studied in pancreatic cancer patients.
What is the filing type and date?
This is a Form 6-K filed on April 30, 2025.
What was Purple Biotech Ltd. formerly known as?
Purple Biotech Ltd. was formerly known as Kitov Pharma Ltd. and Kitov Pharmaceuticals Holdings Ltd.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 30, 2025 regarding PURPLE BIOTECH LTD. (PPBT).